Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 5 May 2014 |
| Trading in Novo Nordisk shares by board members, executives and associated persons on 1 May 2014 | 2 May 2014 |
| Novo Nordisk A/S: Novo Nordisk increased operating profit in local currencies by 15% in the first quarter of 2014 | 1 May 2014 |
| Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme | 30 Apr 2014 |
| Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2014 | 30 Apr 2014 |